Premium
Clinical application of radiophotoluminescent glass dosimeter for dose verification of prostate HDR procedure
Author(s) -
Hsu ShihMing,
Yeh ChienYi,
Yeh TienChi,
Hong JiHong,
Tipton Annie Y. H.,
Chen WeiLi,
Sun ShungShung,
Huang David Y. C.
Publication year - 2008
Publication title -
medical physics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.473
H-Index - 180
eISSN - 2473-4209
pISSN - 0094-2405
DOI - 10.1118/1.3005478
Subject(s) - dosimeter , dosimetry , monte carlo method , brachytherapy , nuclear medicine , medical physics , dose profile , medicine , materials science , radiation therapy , radiology , mathematics , statistics
High dose rate brachytherapy (HDR‐BT) is one of the many modalities for prostate cancer treatment. Due to the nature of HDR‐BT, in vivo dosimetry is feasible and can be used to verify consistent dose delivery. In order to validate a dose verification system for HDR‐BT prostate cancer treatment, a radiophotoluminescent glass dosimeter (RPLGD) was used and the measurements were compared with those from a thermoluminescent dosimeter. The RPLGD shows many advantages in HDR‐BT dose measurement, such as repeatability, stability, and small effective size. These advantages make the RPLGD a superior option for use as a dosimeter in HDR‐BT. The results described here show that the difference between the measured dose and the treatment planned dose is less than 5%. A Monte Carlo simulation for the dose was performed using Monte Carlo N ‐particle to investigate position error. This study concludes that the RPLGD is a promising and reliable dosimeter for HDR‐BT in vivo dosimetry with clinically acceptable accuracy.